On December 19, Gelonghui reported that SSY GROUP (02005.HK) announced that its wholly-owned subsidiary, Shijiazhuang Four Pharmaceuticals Co., Ltd., has entered into a strategic cooperation framework agreement with HIGHTIDE-B (02511.HK) and its wholly-owned subsidiary ("Partner"). The agreement aims to combine the group's extensive experience in active screening, formulation development, achievement transformation, quality, and cost control, along with HIGHTIDE-B's unique advantages in the field of natural product multi-system collaborative innovation, to tackle industry challenges and provide breakthrough solutions for Global metabolic diseases and longevity anti-aging.
石四药集团(02005.HK)与君圣泰医药就共同研发订立框架协议
SSY GROUP (02005.HK) has signed a framework agreement with Junshentai Pharmaceutical for joint research and development.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated